Pfizer CEO Albert Bourla told CNBC on Friday that despite the company’s promising data on an antiviral oral Covid pill, vaccines and vaccine boosters are still important in the fight against the virus.
Pfizer CEO Albert Bourla interviewed on CNBC on Friday where he restated the company’s position that vaccination among healthy adults still stands as the highest priority in fighting the virus. “The fact that we have a treatment is not at all a reason not to take the vaccine, in fact we should take the vaccine,” he said.
Although the pill seems promising it is still in a study and reaserch phase, which means that Pfizer must send in data to the FDA that would show correlation between users and a decrease in the spread and symptoms of COVID.
Since March the Pfizer company initiated studies for a oral antiviral therapeutic pill that can help some individuals in battling the SARS-COV-2 virus. On the Pfizer website recommendation is critically made for suggesting individuals to take the vaccine with priority but then further seeking other treatment solutions.
A statement from their site reads “Tackling the COVID-19 pandemic requires both prevention via vaccine and targeted treatment for those who contract the virus” [
Currently there is high hope for a release of oral pill as many individuals seek to find other methods of treatment in order to end the virus completely considering many people are getting reinfected but with newer mutated viruses.
ARTICLE: JACOB KOVACS
MANAGING EDITOR: CARSON CHOATE
PHOTO CREDITS: CNBC
Latest posts by Jacob Kovacs (see all)
- Elon Musk ends the week selling another $1.2 billion of Tesla shares - November 15, 2021
- Pfizer CEO says COVID-19 vaccines and boosters still needed, even with effective pills - November 9, 2021
- Minneapolis Park Board proposes ‘unprecedented’ funding for expansion of youth programs - November 2, 2021